Atherosclerosis
Conditions
Keywords
darapladib,, SB480848,, Japanese healthy volunteers
Brief summary
This study is being conducted to provide safety, tolerability, PK and PD data in repeat dosing that will allow further studies with darapladib in Japanese patients
Interventions
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
20 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Japanese adult males between 20 and 64 yeas of age, inclusive. * Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-lead ECG, immunology tests and urinary drug screen test. * Bodyweight \>50 kg and body mass index (BMI) between 18.5 and 25.0 at screening. * Subjects must be capable of providing written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. * Baseline QTc interval \<450 msec. * Non-smoker or ex-smoker having ceased smoking for at least 6 months. * Clinical laboratory examination (AST, ALT, ALP and GGT) at screening are within the normal range. * The subject is able to attend all visits and complete the study.
Exclusion criteria
* Any clinically relevant abnormality identified on the screening physical examination, vital sign measurement, 12-lead ECG recording and/or clinical laboratory examination that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern. * History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening. * Positive for urine drug at screening. * Positive for syphilis, HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody or HTLV-1 antibody at screening. * Use of prescription or no-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. * Consumption of grapefruit juice or food within 7 days prior to the first dose of study medication. * A history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology. * Donation of blood in excess of 400mL within 4 months or 200mL within 1 months prior to at screening. * History of drug abuse, or current conditions of drug abuse or alcoholism. * Participation in a clinical study or post-marketing study with an investigational or a non-investigational product or device within 4 months of preceding the first dose of study medication. * Participation in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device. * History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses. * The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms. * History of sensitivity to heparin or heparin-induced thrombocytopenia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety/tolerability of repeat oral doses of darapladib | — |
| Primary Pharmacokinetic parameters of repeat oral doses of darapladib | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Lp-PLA2 activity, expressed in terms of percent inhibition relative to baseline | — |
| Estimation of PK/PD parameters and their associated variability, appropriate to the final models | — |
| -Secondary PK parameters | — |
| -description of plasma concentration-Lp-PLA2 activity inhibition relationship after repeat oral doses of darapladib. all measured same timepoints as primary | — |
| -inhibition of Lp-PLA2 activity | — |
| -PK parameters of SB553253 | — |
| Tmax, and t1/2 of SB-480848 and AUC, Cmax, t1/2 and Tmax of the pharmacologically active metabolite SB-553253 (as data permit) | — |
Countries
Japan
Outcome results
None listed